Reasons for discontinuation of GLP1 receptor agonists: data from a real-world cross-sectional survey of physicians and their patients with type 2 diabetes
Open accessThe DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
AIM: Nonadherence to glucagon-like peptide-1 receptor agonists (GLP1 RAs) is relatively common among patients with type 2 diabetes mellitus (T2DM). This study sought to identify reasons why patients discontinue GLP1 RAs. MATERIALS AND METHODS: Retrospective data from the Adelphi Diabetes Disease Specific Programme were used. Physicians managing patients with T2DM were surveyed via face-to-face interviews, and patients treated for T2DM were surveyed via self-completed questionnaires. Patient data were stratified by current versus prior GLP1 RA use. RESULTS: Physicians (n=443) most frequently reported inadequate blood glucose control (45.6%), nausea/vomiting (43.8%), and gastrointestinal (GI) side effects (36.8%) as reasons for GLP1 RA discontinuation. Patients (n=194) reported the GI-related issues "Made me feel sick" (64.4%) and "Made me throw up" (45.4%) as their top reasons for discontinuation. The most common problems reported (excluding cost) for those currently using GLP1 RAs were "Prefer oral medication over injections" (patients 56%, physicians 32.6%), "Made me feel sick" (patients 38.1%, physicians 16.3%), and "Did not help lose weight" (patients 25.4%, physicians 18%). The most bothersome problems for patients globally (frequency reporting very/extremely bothersome) (excluding cost) were "Difficult to plan meals around" (55.6%), "Made me throw up" (51.6%), and "Caused weight gain" (50%). CONCLUSION: Both patients and physicians reported GI-related issues as a prominent factor, but disparities between patient experiences and physician perceptions were revealed, suggesting gaps in physician-patient communication. Understanding patients' expectations of GLP1 RAs and physicians' patient-management practices may help increase GLP1 RA adherence and thereby potentially enhance diabetes care.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For patients taking these medications for the treatment of obesity, there may be a particular reluctance to continue when weight loss plateaus or weight loss goals are reached”
From The societal implications of using glucagon-like peptide-1 receptor agonists for the treatment of obesity (2025) · cites this paper as [75]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Cost has consistently been cited as one of the most common barriers toward initiating and continuing GLP1-RA treatment, though there are still limited data on GLP1-RAs used solely for weight management.75,97,106”
From The societal implications of using glucagon-like peptide-1 receptor agonists for the treatment of obesity (2025) · cites this paper as [75]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the largest cross-sectional survey of GLP-1 RA discontinuation in routine practice to date, both physicians and patients converged on GI symptoms as a leading cause of treatment cessation, although the relative emphasis differed [54].”
From Adherence and Persistence with GLP-1-Based Therapies: International Real-World Evidence and the Role of Nutritional and Lifestyle Support—A Narrative Review (2026) · cites this paper as [54]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Surveyed physicians (n = 443) most frequently cited inadequate glycemic control (45.6%), nausea or vomiting (43.8%), and other GI side effects (36.8%) as reasons for stopping therapy in their patients; surveyed patients in turn most frequently cited nausea (64.4%) and vomiting (45.4%) as their principal reasons for abandoning treatment.”
From Adherence and Persistence with GLP-1-Based Therapies: International Real-World Evidence and the Role of Nutritional and Lifestyle Support—A Narrative Review (2026) · cites this paper as [54]
In the citing paper
“In clinical practice, GI AEs (most commonly nausea) are known to be a common reason for discontinuation of GLP‐1RA treatment. 41”
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Vilsboll, T., Christensen, M., Junker, A. E., Knop, F. K., & Gluud, L. L. (2012) · BMJ · doi:10.1136/bmj.d7771 · Cited by 970 · cited 1×
“AEs with GLP1 RAs to be GI events, including diarrhea, nausea, and vomiting.(25) Given time, these common AEs usually subside.”
Anderson, P., Benford, M., Harris, N., Karavali, M., & Piercy, J. (2008) · Current Medical Research and Opinion · doi:10.1185/03007990802457040 · Cited by 522 · cited 2×
“A full description of the methodology has been published previously.(7)”
Self-citationA clinical review of GLP-1 receptor agonists: efficacy and safety in diabetes and beyond
Prasad-Reddy, L., & Isaacs, D. (2015) · Drugs in Context · doi:10.7573/dic.212283 · Cited by 365 · cited 1×
“For example, in clinical trials, <5% of patients discontinued a GLP1 RA due to GI effects; however, higher rates, between 5% and 10%, have been observed in clinical practice.(23,24) Clinical trials have reported the most common Figure 2 Reasons for GLP1 RA discontinuation in the past 6 months, ranked by frequency.”
GLP-1 receptor agonists: a review of head-to-head clinical studies
Trujillo, J. M., Nuffer, W., & Ellis, S. L. (2015) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018814559725 · Cited by 282 · cited 1×
“Although clinical trials have demonstrated that GLP1 RAs are effective at reducing HbA 1c levels, these trials have also highlighted the differences in the type, frequency, and severity of adverse events (AEs) compared to insulin and among drugs within the GLP1 RA class.(20,21) Our results suggest the outcomes of thes…”
Higgins, V., Piercy, J., Roughley, A., Milligan, G., Leith, A., Siddall, J., & Benford, M. (2016) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s120101 · Cited by 260
Self-citationBabineaux, S. M., Curtis, B., Holbrook, T., Milligan, G., & Piercy, J. (2016) · BMJ Open · doi:10.1136/bmjopen-2015-010352 · Cited by 253 · cited 1×
“Data used for this analysis are more likely to provide a representative, real-world sample of patients with T2DM and real-world patient behavior than randomized clinical trial data.(10,22) For example, in clinical trials, <5% of patients discontinued a GLP1 RA due to GI effects; however, higher rates, between 5% and 1…”
Self-citation7. Approaches to Glycemic Treatment
American Diabetes Association (2016) · Diabetes Care · doi:10.2337/dc16-s010 · Cited by 225
Seufert, J., & Gallwitz, B. (2014) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12251 · Cited by 156 · cited 1×
“16–19 This study suggests that this is the case for GLP1 RA users, as we found GI issues were three of the top five reasons for GLP1 RA discontinuation for patients across both geographic regions, indicating that patients may place more importance on factors that interrupt daily routines and…”
Elliott, L., Fidler, C., Ditchfield, A., & Stissing, T. (2016) · Diabetes Therapy · doi:10.1007/s13300-016-0157-z · Cited by 153 · cited 1×
“Data used for this analysis are more likely to provide a representative, real-world sample of patients with T2DM and real-world patient behavior than randomized clinical trial data.(10,22) For example, in clinical trials, <5% of patients discontinued a GLP1 RA due to GI effects; however, higher rates, between 5% and 1…”
Florez, H. J., Luo, J., Castillo-Florez, S., Mitsi, G., Hanna, J., Tamariz, L. J., Palacio, A., Nagendran, S., & Hagan, M. (2010) · Postgraduate Medicine · doi:10.3810/pgm.2010.03.2128 · Cited by 126
Cited by
GIPR agonism mediates weight-independent insulin sensitization by tirzepatide in obese mice
Samms, R. J., Christe, M. E., Collins, K. A. L., Pirro, V., Droz, B. A., Holland, A. K., Friedrich, J. L., Wojnicki, S., Konkol, D. L., Cosgrove, R., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci146353 · Cited by 256
“However, although the GLP-1RA class has improved the standard of care, many patients still do not reach their glycemic targets (10), and thus, there remains a need to identify agents capable of complementing the actions of GLP-1RAs.”
BackgroundWharton, S., Davies, M., Dicker, D., Lingvay, I., Mosenzon, O., Rubino, D. M., & Pedersen, S. D. (2022) · Postgraduate Medicine · doi:10.1080/00325481.2021.2002616 · Cited by 236
“However, GI side effects remain the most common reason for patients discontinuing treatment [23].”
BackgroundBorner, T., Geisler, C. E., Fortin, S. M., Cosgrove, R., Alsina-Fernandez, J., Dogra, M., Doebley, S., Sanchez-Navarro, M. J., Leon, R. M., Gaisinsky, J., et al. (2021) · Diabetes · doi:10.2337/db21-0459 · Cited by 202
“Food and Drug Administration-approved GLP-1–based therapeutics elicit nausea and vomiting in a significant percentage of patients, which represent primary reasons for treatment discontinuation (4).”
BackgroundShould metformin remain the first-line therapy for treatment of type 2 diabetes?
Baker, C., Retzik-Stahr, C., Singh, V., Plomondon, R., Anderson, V., & Rasouli, N. (2021) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018820980225 · Cited by 181
Wharton, S., Calanna, S., Davies, M., Dicker, D., Goldman, B., Lingvay, I., Mosenzon, O., Rubino, D. M., Thomsen, M., Wadden, T. A., et al. (2022) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14551 · Cited by 200
“In clinical practice, GI AEs (most commonly nausea) are known to be a common reason for discontinuation of GLP-1RA treatment.(41)”
Background
Metadata
- Authors
- Sikirica, M., Martin, A., Wood, R., Leith, A., Piercy, J., & Higgins, V.
- Affiliations
- GlaxoSmithKline (United States) (US)
- GlaxoSmithKline (United Kingdom) (GB)
- Adelphi Group (United Kingdom) (GB)
- Corresponding author
- Sikirica, Mirko
- Venue
- Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
- Publisher
- Informa UK Limited
- Published
- 2017-09
- Volume
- Volume 10
- Pages
- 403-412
- ISSN
- 1178-7007 (ISSN-L)
- PMC
- PMC5630073
- OpenAlex
- W2763255780
- Cited by
- 223
- References
- 21
- Citations by year
- 2026: 40 · 2025: 54 · 2024: 34 · 2023: 23 · 2022: 21 · 2021: 22 · 2020: 13 · 2019: 11 · 2018: 5
- FWCI
- 6.27
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Diabetes Metabolic Syndrome and Obesity (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc)
- Funders
- GlaxoSmithKline
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Family Practice › Medication Adherence and Compliance
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- GLP-1 receptor agonists, type 2 diabetes, drug discontinuation, medication adherence, gastrointestinal adverse effects, nausea and vomiting, physician-patient communication, patient expectations, weight gain, physician perceptions
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Reasons for discontinuation of GLP1 receptor agonists: data from a real-world cross-sectional survey of physicians and their patients with type 2 diabetes. https://app.cochat.ai/papers/10.2147/dmso.s141235
- The paper
- Sikirica, M., Martin, A., Wood, R., Leith, A., Piercy, J., & Higgins, V. (2017). Reasons for discontinuation of GLP1 receptor agonists: data from a real-world cross-sectional survey of physicians and their patients with type 2 diabetes. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy. https://doi.org/10.2147/dmso.s141235
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.